A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts

A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts

A chemist from RUDN University has created platinum complex compounds that are superior in activity to cisplatin, the drug for the treatment of tumour diseases. The new compounds turned out to be also less toxic to healthy cells.

Platinum-based anticancer drugs — cisplatin, oxaliplatin, and carboplatin — are used for chemotherapy in about half of cancer cases. They penetrate cells and interact with DNA molecules. The process is fatal for rapidly dividing cancer cells because the drugs prevent the duplication of DNA molecules, which is necessary for successful division. Since cancer cells divide rapidly, they are the first to be affected. Still, platinum derivatives have certain disadvantages: low stability under physiological conditions and high toxicity.

To create new drugs, a strategy that involves the development of hybrid molecules is often used in modern chemistry. Such substances consist of two or more active fragments that are linked by a linker into one molecule. They usually have a double action, characteristic of each of the fragments.

A chemist from RUDN University, candidate of biological sciences Kirill Kirsanov, created a series of new drugs: hybrids of cisplatin, lonidamine, and bexarotene. Lonidamine itself has an anti-tumour effect due to its ability to suppress energy metabolism in cancer cells. In combination with radiation therapy, it is used to treat brain tumours. Bexarotene is used for the treatment of lung cancer and breast cancer, as it inhibits the growth of tumour cells of hematopoietic and squamous origin.

A derivative of cisplatin with bexarotene turned out to be the most promising. A combination of succinic acid and ethylenediamine was used as a linker. In tests conducted on four tumour cell lines, the hybrid drug was 80 times more active than bexaroten and 20 times higher on average than cisplatin, and the new drug was 80 times more active than cisplatin on MCF7D cell line. Based on the resulting leading compound, new and more effective anti-tumour medications can be developed.

The paper was published in the journal Inorganica Chimica Acta.

All news
02 Dec
RUDN chemists have created a biodegradable polymer for disposable medical products

RUDN chemists have created a biodegradable polymer based on chitosan and polyhydroxybutyrate. Chitosan, which is obtained from animal shells and fungal cells, gives the compound antimicrobial properties, so it can be used for disposable medical and hygienic materials and products.

29 Nov
RUDN University Mathematician Develops an Approach for Individual Therapy of Haemophilia and Thrombosis

RUDN University professor together with colleagues from France and the USA has developed a technique for describing blood clotting regarding the individual characteristics of patients. This will help to make more accurately diagnosis and select drugs dosages for the treatment of haemophilia, thrombosis and other blood coagulation disorders.

25 Nov
RUDN chemists have found an effective catalyst for the synthesis of raw materials of the chemical industry

RUDN chemists have proven the effectiveness of metal complexes for catalysis of cyanhydrin production — substances important for the chemical industry. Chemists managed to achieve 96.3% of the reaction efficiency.